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Lex J Schouten1, Giedre Kavaliauskiene1, Jurgen H Runge1, Jeroen AW Tielbeek1 and Jaap Stoker1Abstract
Background: Pain is common during colonic insufflation required for CT colonography. We therefore evaluate
whether a single intravenous alfentanil bolus has a clinically relevant analgesic effect compared with placebo in
patients undergoing CT colonography.
Methods: A prospective multi-centre randomised double-blind placebo-controlled trial was performed in patients
scheduled for elective CT colonography. Patients were randomised to receive either a bolus of 7.5 μg/kg alfentanil
(n = 45) or placebo (n = 45). The primary outcome was the difference in maximum pain during colonic insufflation
on an 11-point numeric rating scale. We defined a clinically relevant effect as a maximum pain reduction of at least
1.3 points. Secondary outcomes included total pain and burden of CT colonography (5-point scale), the most
burdensome aspect and side effects. Our primary outcome was tested using a one-sided independent samples t-test.
Results: Maximum pain scores during insufflation were lower with alfentanil as compared with placebo, 5.3 versus 3.0
(P < 0.001). Total CT colonography pain and burden were also lower with alfentanil (2.0 vs. 1.6; P = 0.014 and 2.1 vs. 1.7;
P = 0.007, respectively). With alfentanil fewer patients rated the insufflation as most burdensome aspect (56.1% vs.
18.6%; P = 0.001). Episodes with desaturations < 90% SpO2 were more common with alfentanil (8.1% vs. 44.4%;
P < 0.001, but no clinically relevant desaturations occurred.
Conclusions: A low-dose intravenous alfentanil bolus provides a clinically relevant reduction of maximum pain during
CT colonography and may improve the CT colonography acceptance, especially for patients with a low pain threshold.
Trial registration: Dutch Trial Register: NTR2902
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Patient satisfactionBackground
Computed tomographic (CT) colonography is an accurate
technique for the detection of colorectal cancer and clinic-
ally relevant polyps and it is a less invasive alternative for
colonoscopy [1-7]. In clinical practice CT colonography is
widely used and it has been adopted as colorectal cancer* Correspondence: t.n.boellaard@amc.uva.nl
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reproduction in any medium, provided the orscreening tool in the United States and is considered for
screening in other countries [8,9].
Sufficient colonic distension is mandatory for visualisa-
tion of the bowel wall [10], but insufflation causes the
bowel to stretch and may result in painful colonic cramps
[11-16]. Colonic insufflation is one of the most burden-
some aspects of CT colonography [13-15]. In several stud-
ies the pain and burden scores of CT colonography even
compare unfavourably with conventional colonoscopy
under conscious sedation [11,12,15,16], although in other
studies CT colonography is favoured over colonoscopyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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possible side effects of anxiety [18]) are detrimental for
acceptance of the test, both in clinical practice as in
screening.
During conventional colonoscopy administration of an-
algesics is regular practice. To the best of our knowledge,
no analgesics are administered during CT colonography
and no studies have evaluated this option. To induce suf-
ficient analgesia for acute pain during CT colonography an
opioid is most suitable because of the analgesic potency
[19-21]. Hereby intravenous administration allows more
precise timing of the peak effect compared with oral
administration.
In sigmoidoscopy, a fentanyl bolus has been shown to
improve pain scores [22]. Because of the CT colonography
procedure time is approximately 20 minutes [23] an opi-
oid with a rapid onset and short elimination time would
be suitable and prevents long recovery times. Alfentanil
is such a short-acting opioid (maximum effect within
1–2 minutes and subsequent distribution half life values
of 1 and 14 minutes) [24]. The need for recovery facili-
ties could have negative consequences for its widespread
clinical use for CT colonography and in particular in
screening [25].Figure 1 Flow chart of the study.Before considering the use of opioids during CT colono-
graphy, it is necessary to demonstrate a clinically relevant
pain reduction, beneficial effect on the burden and accept-
ance, without detrimental effects on safety, procedure time
and recovery time.
We hypothesised that a single bolus intravenous
alfentanil will give a clinically relevant reduction in max-
imum pain defined as at least 1.3 point reduction on an
11-point numeric rating scale [26-28].
Methods
Design
We performed a prospective, multi-centre, randomised,
double-blind, placebo-controlled trial to evaluate whether
a single bolus intravenous alfentanil has a clinically rele-
vant analgesic effect in patients scheduled for elective CT
colonography. We evaluated possible differences between
alfentanil and placebo at different time points (Figure 1).
This study was approved by the institutional review board
of the Academic Medical Center and all participants gave
their written informed consent. The study protocol has
previously been described in detail [29] and the trial was
registered in the Dutch Trial Register: NTR2902. The
study was conducted in accordance with the protocol and
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ciples governing clinical research as set out in the Declara-
tion of Helsinki (1989) and Good Clinical Practice (GCP).
The CONSORT 2010 Statement was used as guide for our
reporting [30].
Outcomes measures
The primary outcome was the difference in maximum
pain score between patients receiving alfentanil compared
with placebo. We had defined a clinically relevant effect as
a pain reduction of at least 1.3 point on an 11-point nu-
meric rating scale, as this is considered the minimally im-
portant difference using this scale [26-28].
Secondary outcome measures were differences between
patients receiving alfentanil and placebo regarding: pain
scores per insufflation position, pain and burden of the
CT colonography procedure and individual CT colono-
graphy aspects (e.g. insufflation, bowel preparation etc.),
side effects, vital parameters, procedure time and recovery
time.
Population
Consecutive patients aged 18–85 years and scheduled for
elective CT colonography were assessed for eligibility in
two institutions in Amsterdam, the Netherlands: Academic
Medical Center, University of Amsterdam (academic insti-
tution) and Onze Lieve Vrouwe Gasthuis (teaching hos-
pital). Patients were assessed for eligibility by telephone by
one of the research physicians (T.N.B., M.P.P. or L.J.S.).
CT colonography was performed in symptomatic and sur-
veillance patients only. We used the following exclusion
criteria: heart rate < 50 beats per minute; systolic blood
pressure < 90 mmHg; severe chronic obstructive pulmonary
disease; liver disease defined as a Child-Pugh score of > 4;
alfentanil allergy; pregnancy; increased intracranial pressure;
use of MAO-inhibitors within two weeks before CTcolono-
graphy; use of barbiturates, opiates or daily benzodiazepine.
Power calculation
We powered to detect a difference in maximum pain
score between the placebo and alfentanil group, using
nQuery Advisor 7.0 (Statistical Solutions Ltd., Cork,
Ireland). Based on our anaesthesiologists (S.E. and M.W.H.)
experience a maximum pain reduction of 1.5 points was
expected. A previously performed population screening
trial served as pilot data to assess distribution and stand-
ard deviation [15]. We calculated for a one-sided t-test,
1.5 point difference, 80% power, 0.05 α error and a stand-
ard deviation of 2.6. We assumed 5% withdrawal and
therefore our calculation resulted in groups of 45 patients.
Intervention
Two research physicians (J.H.R. and M.C.H.) generated
a randomisation list using nQuery. The list was kept bythree research physicians (J.H.R., M.C.H. and J.A.W.T.)
not involved in the patient recruitment, CT colonography
procedure or data collection. Included patients were
randomised into two groups of 45 patients (1:1 ratio and
blocks of six). Group 1 received a single bolus of 7.5 μg/kg
actual body weight alfentanil (Rapifen, Janssen-Cilag,
Tilburg, the Netherlands). Group 2 received 0.9% saline
solution as placebo. Both groups received 0.075 mL/kg ac-
tual body weight fluid. Study medication was prepared by
the physicians who kept the randomisation list. The medi-
cation ampule was placed in a signed sealed envelope near
the CT scanner room to allow deblinding in case of a
medical emergency. The study medication was adminis-
tered (double-blind) through a 20 Gauge intravenous can-
nula, 1½ minute following administration of a spasmolytic
agent. After the procedure one of the physicians who kept
the randomisation list collected the envelope.
CT colonography
We used a 24-hour preparation with low-fibre diet and
three or four bottles 50 mL iodinated contrast, meglumine
ioxithalamate (Telebrix, Guerbet, Aulnay sous Bois,
France) [31,32]. For bowel relaxation 1 mL (20 mg) butyl-
scopalamine bromide (Buscopan, Boehringer-Ingelheim,
Ingelheim, Germany) or, if contraindicated 1 mL (1 mg) glu-
cagon (GlucaGen, Novo Nordisk A’S, Bagsvaerd, Denmark)
was used [33,34]. An automated carbon dioxide insufflator
(PROTOCO2L, Bracco, EZEM, Lake Success, USA) and a
flexible 20 French rectal catheter were used with insuffla-
tion in three positions: right decubitus, supine and left de-
cubitus position. We aimed for three litres insufflation
(1.3, 0.8 and 0.9 litres per position, respectively). The in-
sufflation pressure was gently increased during insufflation
(maximum pressure of the insufflator is 25 mmHg) and
set on 20 mmHg when the target volume of three litres
was met or after five minutes of insufflation irrespective of
the target volume. Subsequently scan acquisitions were
performed in prone and supine position and intravenous
contrast medium iopromide (Ultravist 300, Bayer B.V.,
Mijdrecht, the Netherlands) was given in case of clinical
suspicion for colorectal cancer. Prone position was the
first acquisition position when intravenous contrast was
used and the second scan position when only unenhanced
acquisitions were performed.
Evaluation during procedure
Pain scores were assessed with an 11-point numeric rat-
ing scale at the end of prone scan acquisition position
and for all three insufflation positions (0 = no pain and
10 = worst pain imaginable).
During the procedure, patients’ vital parameters were
monitored (PM50, Contec Medical Systems CO, LTD,
Qinhuangdao, China). We registered values at standard
time points: before spasmolytic injection, 1½ minutes
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starting the alfentanil injection. The value 1½ minute
after spasmolytic injection was the reference value for
comparisons with values after study medication injec-
tion, because the spasmolytic can influence the vital pa-
rameters [35]. Heart rate and oxygen saturation were
measured continuously with the same device and stored
measurements were analysed afterwards. Furthermore
all side effects and the time in the scanner room were
recorded.
Monitoring
To evaluate recovery after the procedure the Aldrete
score, a commonly used recovery score [36,37], was as-
sessed at arrival in the waiting room and at 30 and 60
minutes after administration of the study medication
(Figure 2) [38].
Questionnaires
Baseline characteristics, procedure expectations and pro-
cedure experience were assessed using a pre- and post-
procedural questionnaire and largely originated from a
previous study [15]. The pre-procedural questionnaire
consisted of 22 questions and was filled out before ran-
domisation and the post-procedural questionnaire
consisted of 17 questions and was filled out 30 minutes
after the procedure. Questions about expectations in-
cluded burden and pain of the bowel preparation, intra-
venous cannula insertion, bowel insufflation, and the
total procedure on a standard formatted 5-point scale
(not at all, slight, some, rather, and extremely). Identical
questions on experience were asked using the same stand-
ard formatted 5-point scale. Further, the most painful orFigure 2 Modified Aldrete score [38]. The modified Adrete score
was assessed at three time points: at arrival in the waiting room
after the procedure, and at 30 and 60 minutes after study
medication injection. The maximum Adrete score is 10.burdensome aspect was assessed and whether they would
accept CT colonography as a screening test.
Follow-up
All patient symptoms reported to their general practi-
tioner up to one month after the procedure were assessed
for their likelihood of being related to alfentanil by two
blinded anaesthesiologists (S.E. and M.W.H.).
Image evaluation
Two independent observers (T.N.B. and G.K., both eval-
uated > 250 CT- colonographies) evaluated all CT im-
ages for distension, collapse, diagnostic adequacy and
diverticulosis [39]. Evaluation was done for six segments
separately and distension and collapse was also evaluated
for prone and supine separately. Bowel distension was
scored on a 4-point scale based on the worst part of the
segment (0-25%, 25-50%, 50-75% and 75-100% disten-
sion) [40]. The presence of collapse was scored (yes or
no). To assess diagnostic adequacy, observers scored
whether detection of ≥ 6 mm lesions was possible based
on the distension of prone and supine position com-
bined (yes or no). Diverticulosis was scored on a 4-point
scale [41].
Statistics
All calculations were performed using SPSS version 18.0
(SPSS inc., Chicago, Illinois, USA) and a P value of < 0.05
indicated a statistically significant difference. All data
entry was completed before deblinding. For the differ-
ence in maximum pain score during insufflation, we
used a one-sided independent samples t-test. Univariate
analyses were performed with linear regression to iden-
tify possible confounders. The four most influential vari-
ables with a P < 0.1 would be included in a multivariate
analysis.
For time calculations and pain scores per position we
used a two-sided independent t-test. Differences between
categorical values were determined using a Chi-square
test and binary values with the Fishers exact test. A
(weighted) kappa was calculated to assess interobserver
agreement with regards to distension, collapse, diagnos-
tic adequacy and diverticulosis scores. We used the first
observer scores to perform ordered regression for dis-
tension scores. Variables with P < 0.1 in univariable ana-
lysis were added to the regression analysis as confounder
(diverticulosis, BMI and spasmolytic were tested). Logis-
tic regression was used for collapse and diagnostic ad-
equacy scores.
Results
Between May 2011 and June 2012 a total of 179 patients
were screened for eligibility. We included 90 patients, 54
did not consent and 35 were excluded (Figure 1).






Maximum pain score 5.3 (2.5) 3.0 (2.5) <0.001
Pain score
1 right decubitus 1.8 (2.4) 0.4 (1.0) <0.001
2 supine 3.4 (2.6) 1.4 (2.0) <0.001
3 left decubitus 5.1 (2.5) 2.6 (2.2) <0.001
4 prone 3.0 (2.6) 1.6 (2.5) 0.01
Volume CO2 insufflation (litre) 4.6 (1.4) 4.7 (1.2) 0.99
Pressure at end insufflation (mmHg) 22 (20–25) 22 (19–25) 0.81
Procedural time (minutes) 24.4 (4.2) 24.8 (4.7) 0.64
This table provides mean values with the standard deviation between
brackets. Except the pressure at the end of insufflation which is a median
value with interquartile range.
Pain scores 1, 2 and 3 were asked before performing the scan acquisitions.
Pain score 4 was asked with the patient in the prone scan position. No pain
score was asked during the supine scan position.
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(Table 1). All participants filled out pre- and post- pro-
cedural questionnaires and none of the patients was lost
to follow-up.
Evaluation during procedure
Maximum insufflation pain in the alfentanil group was
2.3 (95%CI 1.3-3.4) point lower on the 11-point numeric
rating scale compared with the placebo group (Table 2).
All possible confounders were equally distributed over
the groups and all possible confounders had a P > 0.1 in
the univariate analysis. Therefore we did not perform a
multivariate analysis or correct for confounders.
Significant differences in pain score between the
alfentanil group and placebo group were also present for
all insufflation positions separately. The amount of medi-
cation given, litres insufflation, pressure at the end of in-






Male (%) 44.4 (20/45) 31.1 (14/45) 0.28
Age (years) 62.2 62.7 0.86
Weight (kg) 75.5 76.3 0.83
Height (cm) 172 170 0.41
BMI (kg/m2) 25.6 26.2 0.59
Education (%) 0.83
primary 6.7 (3/45) 6.7 (3/45)
secondary 53.3 (24/45) 46.7 (21/45)
tertiary 40.0 (18/45) 46.7 (21/45)
Ethnicity (%) 0.90
Dutch 93.3 (42/45) 91.1 (41/45)
Surinam 4.4 (2/45) 6.7 (3/45)
other 2.2 (1/45) 2.2 (1/45)
First CT colonography (%) 100 (45/45) 100 (45/45) 1.00
Indication abdominal pain (%) 29.5 (13/44) 15.9 (7/44) 0.20
Spasmolytic (%): 0.60
buscopan 86.7 (39/45) 84.4 (38/45)
glucagon 13.3 (6/45) 13.3 (6/45)
no 0 (0/45) 2.2 (1/45)
Oxygen saturation (%SpO2) 98 98 0.47
Heart rate (b/m) 77.8 79.0 0.70
Systolic blood pressure (mmHg) 155 158 0.59
Diastolic blood pressure (mmHg) 86 89 0.28
Expected burden (1–5) 3 3 0.31
Expected pain (1–5) 3 3 0.46
This table shows mean values, unless indicated otherwise; medians are
presented for oxygen saturation, expected pain and burden.
For all percentage the numbers are given between brackets. No significant
differences were present between baseline characteristics of the two groups.Side effects during CT colonography are summarised
in Table 3. Only dizziness and desaturations (SpO2 <
90% of any duration) were significantly more common
in the alfentanil group. All desaturations resolved spon-
taneously and none of the side effects interfered with the
procedure.Table 3 Side effects
Placebo Alfentanil P value
Nausea 2.2 (1/45) 6.7 (3/45) 0.62
Vomiting 0.0 (0/45) 2.2 (1/45) 1.00
Dry mouth 2.2 (1/45) 0.0 (0/45) 1.00
Blurry vision 4.4 (2/45) 2.2 (1/45) 1.00
Dizziness 4.4 (2/45) 37.8 (17/45) <0.001
Sleepy 0.0 (0/45) 2.2 (1/45) 1.00
Dyspnoeic 0.0 (0/45) 2.2 (1/45) 1.00
Sweating 0.0 (0/45) 2.2 (1/45) 1.00
Pressure sensation 0.0 (0/45) 2.2 (1/45) 1.00
Desaturation (SpO2 < 90%) * 8.1 (3/37) 44.4 (16/36) <0.001
Desaturation >15 seconds
(SpO2 < 90%)
8.1 (3/37) 19.4 (7/36) 0.19
Desaturation (SpO2 < 85%) # 2.7 (1/37) 16.7 (6/36) 0.06
Desaturation >15 seconds
(SpO2 < 85%) #
0.0 (0/37) 0.0 (0/36) 1.00
Irregular heart rhythm 18.9 (7/37) 16.7 (6/36) 1.00
Systolic blood pressure at 5 minutes
(20% decrease)
8.9 (4/45) 11.1 (5/45) 1.00
Diastolic blood pressure at 5 minutes
(20% decrease)
20.0 (9/45) 15.6 (7/45) 0.78
Heart rate at 5 minutes
(20% decrease)
4.4 (2/45) 0.0 (0/45) 0.49
This table shows the percentage of patients with different side effects for the
placebo and alfentanil group.
* All > 15 sec and < 85% desaturations are also counted for this category.
# All < 85% saturations lasted 2–9 seconds, on average 4.2 seconds.
Table 4 Experience questionnaire
Outcome Placebo Alfentanil P value
Average insufflation pain 3.8 (2.1) 1.8 (2.0) <0.001
Insufflation most
burdensome aspect
56.1% (23/41) 18.6% (8/43) 0.001
Insufflation most painful aspect 60.0% (24/40) 34.1% (15/44) 0.053
Advise for screening 92.7% (38/41) 100% (44/44) 0.11
This table shows the mean insufflation pain with standard deviation
between brackets.
For the other outcomes the percentages are provided with the numbers
between brackets.
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Median pain and burden of intravenous cannula inser-
tion were 1 (IQR 1–2) for both groups combined. Me-
dian pain and burden of the bowel preparation were 1
(IQR 1–1.25) and 2 (IQR 1–3) for both groups com-
bined. Other experience questionnaire outcomes are
reported in Table 4. Pain and burden of the insufflation
procedure and total CT colonography procedure were in
favour of the alfentanil group (Figure 3).
Monitoring and recovery
Vital parameters are shown in Figure 4. For both groups
the only significant difference was found between heart rate
baseline measurement 1½ minute after spasmolytic injec-
tion and 5 minutes after study medication injection. As
shown in Table 5, the Aldrete score was only significantly
lower for the alfentanil group at arrival in the waiting room.
Colonic distension
For all segments and both positions combined no correla-
tion was seen between distension scores and randomisationFigure 3 Distribution of pain and burden scores. This figure shows the
insufflation and the total CT colonography procedure. Above the bars the
and burden of insufflation and complete CT colonography procedure weregroup (BMI and diverticulosis were confounders) (P =
0.41). Additionally no difference was found for supine (P =
0.60) and prone (P = 0.54) separately. Alfentanil did not in-
fluence the total number of collapsed segments (P = 0.25),
nor the diagnostic adequacy (P = 0.15). Interobserver agree-
ment was good for distension and diagnostic adequacy
(kappa value 0.62 and 0.65). Interobserver agreement was
very good for collapse and diverticulosis, both 0.81.
Follow-up
Six patients had reported symptoms to the general prac-
titioner in the month after the CT colonography. Three
of these were in the alfentanil group. Two of the com-
plaints were rated as possibly related to alfentanil (i.e.
constipation and dysuria).
Discussion
A single bolus 7.5 μg/kg intravenous alfentanil results in
a clinically relevant reduction in maximum pain during
colonic insufflation required for CTcolonography. Import-
antly, alfentanil also reduced the total pain and burden of
the complete CT colonography procedure. Alfentanil did
not influence the procedure time and with alfentanil fewer
patients considered colonic insufflation the most burden-
some aspect of CT colonography. Dizziness and desatura-
tions were the most common side effects of alfentanil,
though recovery times were short.
The reduction of maximum pain was more than the
1.3 points on an 11-point numeric rating scale as we
hypothesised and which is considered the minimum clini-
cally relevant difference [26-28]. For this scale, a pain
score reduction of 2–2.4 points or 33-35% may be of even
greater clinical importance [26,27,42]. Both these criteriadistribution of pain and burden scores (5-point scale) of colonic
medians, means and P values are presented (from top to bottom). Pain
significantly lower with alfentanil.
Figure 4 Vital parameters. Systolic and diastolic blood pressure, the heart rate and saturation over time for the alfentanil and placebo group.
* indicates a significant difference.Statistical differences were calculated between the reference measurement 1 ½ minutes after spasmolytic and
5/10 minutes after alfentanil injection. The heart rate was significantly higher after 5 minutes for both placebo and alfentanil group. No other
significant differences were observed.
Table 5 Median aldrete scores
Time point Placebo Alfentanil P value
Arrival 10 (9–10) 9 (9–10) 0.047
30 minutes 10 (9–10) 9 (9–10) 0.16
60 minutes 10 (9–10) 9 (9–10) 0.10
This table shows median values with interquartile ranges of the Aldrete scores
at arrival, 30 minutes and 60 minutes after study medication injection.
Eight was the lowest Aldrete score in both groups.
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during the prone scan acquisition position was 3.0 in the
placebo group and thus lower than during the left decubi-
tus position, likely due to decreased pressure after initial
insufflation or habituation to the insufflated colon [41].
Importantly, also the pain and burden of the total CT
colonography procedure were reduced. The effect of
alfentanil was more evident on the most burdensome as-
pect, than on the most painful aspect. This is likely be-
cause patients experience the bowel preparation as
burdensome, but not as painful. With alfentanil, the in-
sufflation becomes less burdensome and therefore the
burden of the bowel preparation becomes relatively
more important.
The observed dizziness and desaturations are known
side effects of alfentanil. The desaturation in the placebo
group may indicate that some patients experience spon-
taneous desaturations during the day. Importantly, all
desaturations were not clinically relevant, because they
were short and self-limiting we did not had to perform
any intervention.
Although we found desaturations with alfentanil, we
did not find a SpO2 reduction at 5 and 10 minutes afteralfentanil injection. Conti et al. observed a significant
saturation reduction with a 10 μg/kg bolus intravenous
alfentanil in ASA 1 patients during minor surgery or en-
doscopy [43].
In colonoscopy opioids are commonly used in combin-
ation with a benzodiazepine to induce amnesia. We did
not consider this mandatory for CT colonography while
this combination leads to a greater respiratory depressant
effect than opioids only. The benzodiazepine-induced
drowsiness may complicate the CT colonography proced-
ure and recovery facilities may be required.
A number of limitations have to be acknowledged.
The dizziness caused by alfentanil may have partly af-
fected the double blind character of the trial. We had
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is available that causes dizziness in an equal number of
patients as alfentanil and that does not affect the out-
comes. We chose to use 0.9% saline solution for the pla-
cebo group because it was the solvent for alfentanil and
the viscosity and colour was similar to that of alfentanil.
Importantly, patients were not aware that dizziness
would be more likely related to alfentanil administration
than placebo. Pain was assessed in prone scan acquisi-
tion position only, as we wanted to limit the number of
questions and the pressure is higher in prone position
[41]. The time of prone scan acquisition differed some
minutes between studies with and without intravenous
contrast medium. The influence of prone score on the
maximum pain was negligible as these were much lower
compared with left decubitus. We chose to use an 11-
point numeric rating scale, which is a commonly used
scale [26,44]. The visual analogue scale [44] is also com-
monly used, however this scale is less practical during
colonic insufflation on a narrow table, while having co-
lonic cramps and being monitored. Additionally, we have
experience with the 11-point numeric rating scale during
CTcolonography. For the Aldrete score, we chose as refer-
ence values blood pressure and heart rate measurements,
recorded 1½ minute after injection of the spasmolytic
agent. Most patients received butylscopalamine bromide,
which increases the heart rate [35]. As the effect of the
spasmolytic decreases over time, the heart rate also de-
creases. Furthermore, most patients are nervous at the be-
ginning of a medical procedure and calm down in the
course of the procedure. Both factors might have
influenced Aldrete score negatively, although all patients
had a normal heart rate and blood pressure after the pro-
cedure. Despite the fact the side effects of alfentanil were
of minor clinical relevance and the benefit-risk ratio seems
to favour alfentanil, a safety profile cannot be made based
on 45 patients. Although other studies also have shown
safe use of a single bolus low-dose alfentanil [43,45], more
data on patient safety is warranted.
When alfentanil is used it is important to realise that
monitoring and airway intervention equipment and suf-
ficient knowledge about the pharmacology of opioids
and airway interventions should be present. This means
that the attendance of a physician is required. For institu-
tions were a technician is performing the CT colono-
graphy procedure, adjustments will have to be made in the
procedure. All patients receiving intravenous alfentanil re-
quire an intravenous cannula, so emergency medication
can be given. The above mentioned issues may lead to an
increase in costs. Furthermore, when using alfentanil the
patients need to arrange transportation, because driving
after alfentanil injection is not allowed for 12–24 hours
minimum; this can be a large hurdle for implementation
of alfentanil [24]. Patients who receive butylscopalaminebromide during CT colonography are already advised not
to drive just after the procedure, as this may affect the
ability to drive. Because of disadvantages such as the in-
ability to drive, the lack of analgesia has been mentioned
as one of the advantages of CT colonography [46,47].
Conclusions
To the best of our knowledge we are the first to study
the use of analgesia for CT colonography. Our study
shows that alfentanil provides a clinically relevant reduc-
tion in maximum pain in CT colonography, reduces
total procedural pain and burden, without detrimental
effects on procedural time, recovery time and patient
safety. Although desaturations were frequently observed
with alfentanil, these were not considered clinically rele-
vant because they were all short-lasting and self-limiting.
Therefore alfentanil may well be an option to improve
acceptance, although it may impact the logistics associ-
ated CT colonography examinations. Now that we know
the advantage of alfentanil it can be weighed against the
practical hurdles, side effects and costs. Especially for
patients with a low pain threshold, a low-dose intraven-
ous alfentanil bolus may be viable option. Our secondary
outcomes such as the total procedural pain and burden,
the effect on procedure time and recovery time should
be confirmed in for these outcomes appropriately
powered studies. Furthermore, additional data on a low-
dose intravenous bolus injection alfentanil during CT
colonography is required to further assess the safety
profile.
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